Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1764)	7/6/1998 11:03:00 PM
From: Cisco	Read Replies (2) \| Respond to of 1894

Sigmund, I am not sure the evaluation of the microbiology division is as straight forward as it might seem. Consider the following: You had BioMerieux late last year filing to block a European patent relating to a portion of the almarblue microbiology technology. On Feb 20, 1998 year you had Akzo Nobel officially notifying the company that its manufacturing and selling of the ESP instrument infringed on one of their patients. Thirteen days later you have AccuMed announcing it was looking for a buyer of the Microbiology Division. Any connection???? One thing we do know is that AccuMed paid $6 million for the ESP line! We also know that for the year ending Dec 31, 1997 they had total ESP sales of $2.6 million with gross profits of $668,000 for a loss of $313,000 on the ESP line. Cisco